Bioneer, a genetic engineering company, has recorded its highest quarterly revenue to date and announced significant progress in hair loss research, leading to a surge in its stock price.
As of 1:14 PM on August 19, Bioneer shares were trading at 9,190 won, up 2,120 won (29.99%) from the previous trading day, according to the Korea Exchange.
Analysts attribute the rise in investor sentiment to improved second-quarter results and the publication of hair loss-related clinical trial results in the official journal of the American Academy of Dermatology.
Bioneer reported that its consolidated revenue for the second quarter reached approximately 96.1 billion won, an 8.9% increase compared to the same period last year, marking the highest quarterly revenue in the company's history. The cumulative revenue for the first half of the year was about 177.9 billion won.
Profitability also improved. After recording an operating loss of about 500 million won in the first quarter, the company turned a profit in the second quarter. Bioneer explained that the increase in revenue, alongside a rise in research and development expenses for new drugs by approximately 1.4 billion won compared to the previous quarter, contributed to this improvement.
On the same day, Bioneer announced its hair loss research results, further boosting its stock price.
The company revealed that the results of a clinical trial confirming the applicability of its Cosmerna follow-up technology were published in the 'JAAD,' the official journal of the American Academy of Dermatology. Bioneer stated, "Based on these research results, we are actively considering the commercialization of Cosmerna follow-up products utilizing DKK1 targeting technology."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.